MAIL MAN

[righty]

FROI Closing Correction "Pyro Pharmaceuticals, Inc."
Sun, December 13, 2009 9:56:03 AMFrom: Editor <[e-mail]>Add to Contacts



--------------------------------------------------------------------------------





Presents

Pyro Pharmaceuticals, Inc.
Stock Symbol : FROI



Subscribers,

You are receiving this company image marketing profile again with a corrected price to $0.55. This is an exciting company profile so do your due diligence and please enjoy the due diligence I have done below.

Harold








Pyro Pharmaceuticals, Inc. (OTCBB: FROI)


Pyro Pharmaceuticals is a development stage drug research and development company. Pyro’s mission is clear and concise: to identify, evaluate and acquire new promising antibiotic therapeutic treatments against multi-drug resistant infectious microorganisms in humans.

Recent Price $.55
Market Capitalization
$12.7 M

Est. Float
N/A

Outstanding Shares
25.5 M

Exchange
OTCBB





Fero Industries, Inc.
17 Reeves Crescent
Red Deer, ALB T4P 2Z4
Canada


http://www.pyropharmaceuticals.com



Similar Companies in Sector




• Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkins lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington. Nasdaq: CTIC $1.13.

• Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company?s product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), an investigational active immunotherapy for the treatment of patients with breast, ovarian, and other solid tumors expressing HER2/neu. NASDAQ: DNDN $25.31.




Current Projects




Fero Industries to Acquire Pyro Pharmaceuticals, Inc.'s Enzyme Identification Methodology under Definitive Agreement

Fero Industries, Inc. recently announced that it is acquiring Pyro Pharmaceuticals, Inc.’s patented enzyme identification methodology through its pending acquisition of Pyro Pharmaceuticals. As previously announced, Fero has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro’s capital stock for shares of the Company’s common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009. Fero Industries, Inc. Discloses Growth Through Acquisition Strategy

Fero Industries, Inc. recently disclosed its growth strategy. FROI’s first acquisition target is Pyro Pharmaceuticals, Inc., a boutique developmental stage pharmaceutical company located in Irvine, CA. Pyro’s focus is on developing a new class of antibiotics to fight drug resistant bacteria, such as MRSA.
Pyro has one issued and ten patents pending that protect a new class of antibiotics, geared towards those bacteria resistant to currently available drugs.




Company Overview


Pyro Pharmaceuticals, Inc. (OTCBB: FROI)

Pyro Pharmaceuticals is a development stage drug research and development company. Pyro’s mission is clear and concise: to identify, evaluate and acquire new promising antibiotic therapeutic treatments against multi-drug resistant infectious microorganisms in humans.

Pyro’s focus is on diseases in which antibiotic resistance has become a significant issue. Pyro plans to develop a new class of antibiotics for a wide variety of pathogenic microorganisms, especially those that have exhibited multiple drug resistance. Except for daptomycin (Cubicin® – 2003), which has a distinct mechanism of action, there have been no new classes of antibiotics approved in the United States in over 35 years.

Pyro’s portfolio of drug target patents forms the basis to develop these new antibiotics. Since its inception in 2001, Pyro has successfully obtained one issued patent and has ten patent applications pending.

Fero Industries, Inc.
17 Reeves Crescent
Red Deer, ALB T4P 2Z4
Canada

http://www.pyropharmaceuticals.com



Market Overview
The U.S. antibiotic market is currently at $27.54 billion. Analysts say even a niche antibiotic can generate $200 million in annual sales worldwide; a powerful, broad-ranging drug could easily be a $1 billion product.

BioWorld data shows that the total number of annual bio-partnering deals has doubled from 600 in 1997 to more than 1,200 in 2007, led by approximately 400 biotech-big pharma collaborations in 2007. This was followed closely by more than 300 biotech-academia/non-profit deals and biotech-biotech partnerships, both with more than 300 each.

There has been no abatement in 2009. Deals continue to overshadow drugs as the defining industry trend. Partnering transactions continue at record-breaking rates and financial levels, while annual FDA approval rates remain flat. The deal is still the thrill in drug development markets, as biotechnology innovation continues to be the temptation from which big pharma cannot afford to abstain.

http://www.ebdgroup.com/partneringnews/?q=node/90

Antibiotic resistance is a growing public health concern worldwide. According to the Center for Disease Control (“CDC”), antibiotic drug resistance has significantly increased mortality rates, making infectious disease the third largest cause of death in the United States. Drug resistance has also increased the cost of health care delivery. When antibiotics do not work, the result can be:

Longer illnesses
More complicated illnesses
More doctor visits
The use of more toxic and more expensive drugs
More deaths caused by bacterial infections
Examples of the types of bacteria that have become resistant to antibiotics include the species that cause skin infections, meningitis, sexually transmitted diseases, respiratory tract infections such as pneumonia and tuberculosis, and multi-drug resistant Staph aureus (MRSA).


Frost & Sullivan has identified the following major trends affecting the emerging antibiotics market:

The emergence and widespread use of antibiotics in clinical therapy have increased selective pressure.
Virulent pathogens are developing multiple mechanisms of resistance.
Antibiotic resistance is increasing globally, penetrating class, age, ethnicity, and regional barriers.
Downward price pressures created by generic drugs entering the market, while many blockbuster antibiotics come off patent.
Managed care formularies are demanding that physicians use more cost-effective antibiotics.
Improved pharmacokinetic profiles of many newer agents will permit less frequent dosing, thus reducing costs associated with antibiotic administration.
Frost & Sullivan has identified the following major drivers impacting the emerging antibiotics market:

Continued over-prescription and mis-prescription increases prevalence of resistance.
Genomics technology provides many potential novel target candidates and increases probability of drug discovery.
Commoditization of older antibiotics increases use and bacterial resistance, thus creating need for novel therapies.
Increasing global resistance creates a large unmet need for effective antibiotics.
Widespread use of antimicrobial products in non-therapeutic environments will likely contribute to increasing resistance.
Antibiotics deemed effective against specific chronic diseases increase prescriptions and patient use.
Widespread Internet accessibility provides global genomic and epidemiological information on antibiotic resistance, leading to better information for developing effective novel products.
Use of expensive novel therapies that are more cost-effective than traditional therapies.
Perceived public health crisis, creates willingness to fund development of novel therapies outside traditional pharmaceutical arena.
Pyro is poised to capitalize on the need for new antibiotics to supplant the dwindling arsenal. With one issued and ten pending patents, the Company is researching a new class of antibiotics to overcome these issues.

Business Strategy

The future success of biotech companies will rely on partnering with large pharma. Analysts say even a niche antibiotic can generate $200 million in annual sales worldwide; a powerful, broad-ranging drug could easily be a $1 billion product.
- The New York Times


Pyro has one issued and ten patents pending that protect a new class of antibiotics, geared towards those resistant to currently available drugs. The Company’s goal is to avoid a Superbug catastrophe for which no effective treatment currently exists. Pyro expects that the successful completion of its research will put the Company in a position enter either in-licensing or out-licensing agreements with major biotechnology or pharmaceutical companies.

Biotech-pharma licensing arrangements have been the predominant business strategy in the industry during the last several years. This trend is expected to grow well into the next decade. Big pharmaceutical companies are projected to receive approximately 40% to 50% of their revenue from in-licensed products and more early stage deals, with higher valuations, are taking place as compared to later stage deals (Pharmalicensing, 2006).

Pyro is focused is on developing a new class of antibiotics to fight diseases caused by resistant bacteria. This new class of antibiotics will improve the mortality and morbidity caused by a wide variety of pathogenic microorganisms, especially those that have exhibited multiple drug resistance.

In summary, the combination of the following key parameters differentiates Pyro from other biotechnology companies on the market:

To maximize benefits to shareholders, our corporate focus is devoted to identification, evaluation and acquisition of drug targets and new chemical entities which bring subsequent value addition.

We have a world-class Management Team and Scientific Advisory Board directing all activities.

A pipeline of patents against resistant bacteria and acquisition candidates under evaluation from global collaborations with other biotechnology companies and universities provides significant value to the Company.

Well-implemented strategy of acquiring candidates which target indications having significant unmet needs and with eventual blockbuster potential.

Highly flexible organization and low fixed overheads due to our innovative outsourcing strategy.

Leverage and optimal use of resources based on collaboration with well-established service providers and academic laboratories.

Highly professional approach characterized by swift, responsive and well thought out decision-making and ability to redirect research and business efforts quickly and at low cost, to maximize partnering activities.
Research Collaborations

Collaborations with university researchers are an essential part of Pyro’s strategy. The price of acquiring promising medicines from biotech firms is soaring, reflecting big pharma’s growing hunger for assets to fill their thinning pipelines.

- Reuters


Today, it is essential that biotech and pharmaceutical business strategy include early stage collaborations as a core component. This early stage collaboration allows companies to access promising new and emerging compounds by sponsoring funded research programs with top medical university researchers around the world. Pyro has funded research projects with the following institutions:

SRI International (formerly Stanford Research Institute)
Rockefeller University
Public Health Research Institute (affiliated with NYU Medical School)
Tufts University School of Medicine
Colorado State University
University of California, Irvine School of Medicine



Management


Experienced Management…
Alan M. Schechter, Chairman and CEO. Mr. Schechter is a successful, entrepreneur with a 30 year track record in medical devices and biotechnology. He has raised over $40 million and performed over $250 million in mergers and acquisitions. In addition, he has successfully orchestrated acquisitions and joint ventures with large, publicly traded medical device and biotechnology companies. Mr. Schechter has been a CEO of six previous companies, having been involved with four start-ups and two turn-arounds. Mr. Schechter holds eight U.S. patents in the area of automated, minimally invasive tissue morcellation technology and has fourteen other patents pending. Mr. Schechter has several advanced degrees in Biochemistry and an MBA in Finance. Mr. Schechter sits on the board of several private companies and community related entrepreneurial organizations including Chairman of the California Venture Forum, Chairman of the Orange County Biotechnology Alliance, and Chairman of the Ecumenical Council.

Walter Wallach, Vice President and CFO. Mr. Wallach has more than 30 years of senior management experience with medical and consumer products start-up, mid-sized, and large high growth companies where he has served as Chief Financial Officer, Chief Operating Office or Chief Executive Officer. Three of these were privately held firms and were sold, while one advanced through the initial public offering (IPO) stage. His qualifications and experience include: strong leadership and strategic skills, IPO experience, effective cash flow, balance sheet and Profit & Loss management, strong analytical and communication skills, and experienced at international business in a multinational corporation setting. Mr. Wallach has a MBA in Marketing and a BS Degree in Accounting from Long Island University.

Rich B. Meyer, Ph.D., Vice President of Drug Discovery. Dr. Meyer is a medicinal chemist with expertise in the design and synthesis of nucleoside/nucleotide and enzyme based inhibitor compounds. Dr. Meyer was Vice President of Chemistry/Drug Discovery at Microbe Corporation and Vice President of Research and Development at Epoch Biosciences, Genelabs Technologies, and Protogene Laboratories. Prior to transitioning to industry Dr. Meyer was a Professor of Chemistry at the University of California, San Francisco and Washington State University. Dr. Meyer has a B.A. in Chemistry from Rice University and a Ph.D. in Chemistry from the University of California, Santa Barbara. He did postdoctoral training at the McArdle Laboratory for Cancer Research, University of Wisconsin under the direction of Dr. Charles Heidelberger.








News Headlines



FERO INDUSTRIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibi EDGAR Online (Thu, Dec 10)
Fero Industries, Inc. Discloses Growth Through Acquisition Strategy Business Wire (Wed, Dec 9)
FERO INDUSTRIES, INC. Financials EDGAR Online Financials (Thu, Nov 19)
Pyro Pharmaceuticals, Inc. Announces the Appointment of Robert C. Moellering, Jr., M.D. as Chairman of the Scientific Advisory Board Business Wire (Tue, Nov 10)
Pyro Pharmaceuticals, Inc. Discloses Information on its Ten Patent Applications Business Wire (Mon, Oct 26)
Fero Industries to Acquire Pyro Pharmaceuticals, Inc.'s Enzyme Identification Methodology under Definitive Agreement Business Wire (Thu, Oct 22)
Fero Industries, Inc. Acquisition Target, Pyro Pharmaceuticals Appoints New Board Member Business Wire (Wed, Oct 21)
Pyro Pharmaceuticals Chairman and CEO, Alan M. Schechter, is Slated to Lead the Combined Fero Industries and Pyro Business Wire (Thu, Oct 15)
FERO INDUSTRIES, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and Exhi EDGAR Online (Wed, Oct 14)
Fero Industries Enters into Definitive Agreement to Acquire Pyro Pharmaceuticals Business Wire (Wed, Oct 14)










Disclaimer & Release of Liability




WillyWizard.com owned by First Alert Financial LLC is referred to herein collectively as the "LLC Company" when the context of the statements pertain to compensation matters, including our "Compensation Disclosure" section that seeks to comply with all SEC disclosure regulations for consideration received or to be received, directly or indirectly, from an issuer, underwriter, or dealer, must disclose the receipt and amount, whether past or prospective, of such consideration.

PLEASE NOTE: The LLC Companies and/or its affiliates are not registered as Investment Advisors in any jurisdiction whatsoever.

Release of Liability: Through use of the LLC Company email newsletters and website you agree to hold the LLC Company/WillyWizard.com, its operators, owners, and employees harmless and completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. The LLC Company and/or its affiliates may from time to time have positions in the securities mentioned herein, may increase or decrease such positions without notice, and may profit from such transactions. The hiring party may have shares and may liquidate, which may affect the stock's price. Any opinions expressed are subject to change without notice. The LLC Company encourages readers and investors to supplement the information in these reports with independent research and other professional advice.

Please read our full disclaimer at http://www.willywizard.com

The LLC Company has been compensated four thousand dollars by K.C. for one week (12/11 - 12/17) services to publicly and electronically disseminate information pertaining to FROI.

©2000-2009 WillyWizard.com owned by First Alert Financial LLC 09



sent from: First Alert Financial LLC, 1013 S.E. 125th Ave., Vancouver, WA 98683. You can modify/update your subscription via the link below. Email Marketing by




Manage your subscription
Share this message with others: del.icio.us Digg reddit Facebook StumbleUpon